论文部分内容阅读
为评价目前瑞典斯德哥尔摩乙型肝炎(HB)免疫方案,作者对212名HBsAg阳性母亲的婴儿进行了为期2～9年随访。 按HBsAg阳性孕妇的HBeAg情况分成三组:第1组HBeAg阳性;第2组HBeAg和抗-HBe均阴性;第3组HBeAg阴性,抗-HBe阳性,该组复分为接种疫苗和未接种疫苗两小组。婴儿出生后1小时内,肌肉接种HB疫苗5μg(血源或重组疫苗,均为美国MSD制造)。第1组首针时加用乙型肝炎免疫球蛋白(HBIG)5ml;3周龄和2月龄时分别接种第2及第3剂HB疫苗。用放射免疫法或酶联免疫吸附试验检测HBsAg、HBeAg、抗-HBe、抗-HBc和抗-HBs。
To assess the current hepatitis B (HB) immunization program in Stockholm, Sweden, the authors conducted a 2 to 9-year follow-up of 212 HBsAg-positive mothers. HBsAg-positive pregnant women HBeAg situation is divided into three groups: Group 1 HBeAg positive; Group 2 HBeAg and anti-HBe were negative; Group 3 HBeAg-negative, anti-HBe positive group divided into vaccinated and unvaccinated Two groups. Within 1 hour after birth, the mice were inoculated intramuscularly with 5μg of HB vaccine (blood source or recombinant vaccine, all manufactured by MSD in USA). In the first group, 5 ml of hepatitis B immunoglobulin (HBIG) was added to the first needle, and the second and third doses of HB vaccine were inoculated at 3 weeks and 2 months of age respectively. HBsAg, HBeAg, anti-HBe, anti-HBc and anti-HBs were detected by radioimmunoassay or enzyme-linked immunosorbent assay.